Clinical Conversations (CE): T-Cell-Engaging Bispecific Antibodies in Cancer: What the Non-Oncology Pharmacist Needs to Know about Acute Toxicities (CE)
T-cell-engaging bispecific antibodies represent a major therapeutic and scientific advancement in the treatment of several types of cancer. However, they carry a risk of some unique acute toxicities, such as cytokine release syndrome and neurologic toxicity. This podcast reviews this emerging drug class and strategies for recognition and management of their unique adverse events.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.